Skip to main content
SpringerLink
Log in

Hospice use may not reduce costs in end-stage renal disease

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

References

  1. Wachterman MW, et al. Association Between Hospice Length of Stay, Health Care Utilization, and Medicare Costs at the End of Life Among Patients Who Received Maintenance Hemodialysis. JAMA Internal Medicine : 30 Apr 2018. Available from: URL: http://doi.org/10.1001/jamainternmed.2018.0256.

  2. Schwartz ML, et al. Hospice Use and End-of-Life Care for Patients With End-stage Renal Disease: Too Little, Too Late. JAMA Internal Medicine : 30 Apr 2018. Available from: URL: http://dx.doi.org/10.1001/jamainternmed.2018.1078.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hospice use may not reduce costs in end-stage renal disease. PharmacoEcon Outcomes News 803, 14 (2018). https://doi.org/10.1007/s40274-018-4941-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4941-z

Search

Navigation